Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by HighTide Therapeutics Inc. EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies September 10, 2024 From HighTide Therapeutics Inc. Via ACN Newswire HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801) June 21, 2024 From HighTide Therapeutics Inc. Via ACN Newswire HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) June 04, 2024 From HighTide Therapeutics Inc. Via ACN Newswire HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) January 11, 2023 From HighTide Therapeutics Inc. Via ACN Newswire HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations January 05, 2023 From HighTide Therapeutics Inc. Via ACN Newswire HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology January 06, 2022 From HighTide Therapeutics Inc. Via Business Wire HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021 October 28, 2021 From HighTide Therapeutics Inc. Via Business Wire HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients September 21, 2021 From HighTide Therapeutics Inc. Via Business Wire HighTide Therapeutics Announces the Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021 June 21, 2021 From HighTide Therapeutics Inc. Via Business Wire HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China May 27, 2021 From HighTide Therapeutics Inc. Via Business Wire HighTide to Present at the BofA Securities 2021 Health Care Conference April 28, 2021 From HighTide Therapeutics Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
